Scope
The AAO Preferred Practice Pattern treats acute symptomatic retinal or ophthalmic artery occlusion as an eye and systemic vascular emergency. Priorities are immediate stroke-centre assessment, recognition of giant cell arteritis, identification of embolic or other systemic disease, and surveillance for neovascular complications. The approved source distinguishes these urgent presentations from incidentally detected asymptomatic plaques or branch occlusions.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Treat acute symptoms as a systemic vascular emergency
- Acute symptomatic central, branch or ophthalmic retinal arterial occlusion requires immediate referral to a stroke-centre emergency department. If no stroke centre is available, use an emergency department and communicate that the patient has had an eye stroke. [1]
- Sudden painless monocular loss of acuity or field should raise suspicion. The classic retinal whitening and cherry-red spot can be absent or subtle early; absence of these fundus signs does not provide reassurance against an acute occlusion. [1]
- Ancillary ocular tests may clarify the diagnosis but must not delay stroke-centre transfer for acute nonarteritic retinal artery occlusion. Evaluation aims to identify systemic disease and prevent subsequent cerebral or cardiac vascular events. [1]
- Any-age retinal or ophthalmic artery occlusion warrants systemic stroke evaluation for an embolic source. In older patients consider giant cell arteritis; younger patients may need investigation for vasculitis or hypercoagulability. [1]
- For asymptomatic branch retinal artery occlusion or an incidental asymptomatic arterial plaque, arrange a primary-care systemic vascular assessment. This outpatient pathway must not be applied to acute symptomatic retinal ischaemia. [1]
Identify and act on suspected giant cell arteritis
- In patients over age 50, ask about headache, scalp or temporal tenderness, jaw claudication, fever, fatigue, diplopia and polymyalgic symptoms. The source notes that some patients with giant cell arteritis lose vision without systemic symptoms. [1]
- Obtain ESR, CRP and a blood count with platelets in patients over 50 with central retinal or ophthalmic artery occlusion unless a clear causative plaque is seen, especially if arteritis symptoms are present. Normal inflammatory markers do not fully exclude giant cell arteritis. [1]
- When giant cell arteritis is strongly suspected, begin systemic corticosteroids urgently and arrange temporal artery biopsy. The goal includes preventing fellow-eye visual loss and systemic vascular complications; monitor diabetes carefully because steroids can destabilize glycaemia. [1]
Direct history, examination and investigations
- Record visual-loss duration, embolic or neurological symptoms, medical and medication history, vascular risk factors, smoking, ocular trauma, injections and surgery. This history helps target the systemic investigation. [1]
- Assess visual acuity, pupils, intraocular pressure and anterior/posterior segments. Perform gonioscopy if iris neovascularization is present or suspected or pressure is elevated, ideally recognizing anterior new vessels before dilation. [1]
- OCT can show acute inner-retinal swelling and hyperreflectivity, with later thinning. Angiography may delineate retinal and choroidal perfusion; poor choroidal circulation suggests ophthalmic artery occlusion or arteritis. These tests supplement, rather than postpone, urgent systemic care. [1]
- Without a clear embolic or other cause, evaluate for antiphospholipid antibodies, haematological disorders, autoimmune disease and hypercoagulability. Consider Susac syndrome in younger patients with multiple or recurrent branch occlusions and ask about trauma-related neck or facial pain suggesting carotid dissection. [1]
Prevent complications and support function
- The PPP finds uncertain evidence for interventions intended to restore vision in nonarteritic retinal artery occlusion. Ocular massage, anterior-chamber paracentesis and other traditional conservative measures have not demonstrated significant benefit; this uncertainty does not reduce the need for immediate stroke assessment. [1]
- Monitor central or branch retinal artery occlusion, including combined arterial and venous occlusions, for neovascularization. Greater ocular ischaemia needs more frequent follow-up; routine prophylactic panretinal photocoagulation should wait until neovascularization appears. [1]
- With retinal or anterior-segment neovascularization, give prompt panretinal photocoagulation. Anti-VEGF treatment may supplement or facilitate laser, including when haemorrhage limits visualization; it does not establish restoration of vision already lost from arterial infarction. [1]
- Coordinate vascular secondary prevention with the medical team. The source supports antiplatelet and statin therapy for most affected patients and treatment of atrial fibrillation, alongside smoking cessation and control of hypertension, diabetes and lipid disorders. [1]
- At follow-up, reassess visual symptoms, pain, neurological changes and systemic risk control; examine acuity, iris, pressure and angle for new vessels and the posterior segment. Communicate eye findings promptly to clinicians managing systemic disease. [1]
- Offer visual-rehabilitation and social-service referral for functionally limiting visual loss. Consider counselling, vocational support or peer groups when anxiety, depression or loss of independence or employment follows the occlusion. [1]
Limitations and use
- This summarizes the approved PPP’s clinical pathway, not a complete acute stroke or giant-cell-arteritis prescription. Its discussion does not establish a definitive vision-restoring intervention; acute eligibility and treatment decisions belong to the stroke and ophthalmology team. An inconsistent drug-class term in the source’s acute-treatment discussion is not used to construct a thrombolysis rule here. Carotid procedures, antithrombotic selection and corticosteroid doses require the full relevant specialist guidance.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Retinal and ophthalmic artery occlusions
Guideline recommendation text consulted
Publication details
- Issuing organisation
- AAO
- First published
- 7 February 2025
- Resource type
- Preferred Practice Pattern guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.